About Us


We are a clinical-stage pharmaceutical company discovering and developing novel drug candidates to treat inflammation, inflammatory pain, and blood cancers. We are dedicated to advancing novel therapeutics that we believe will make a clinically meaningful difference in patients’ lives.

Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5'-phosphatase 1, or SHIP1, an enzyme that plays a role in an important cellular signaling pathway in immune cells, known as the PI3K pathway. Aquinox has a broad intellectual property portfolio and pipeline of drug candidates that activate SHIP1.

Rosiptor (AQX-1125), Aquinox's lead drug candidate, has completed recruitment in a Phase 3 clinical trial in interstitial cystitis/bladder pain syndrome (IC/BPS). By activating SHIP1, rosiptor is believed to decrease the inflammatory process, thereby reducing inflammation and inflammatory pain.


We believe rosiptor is suitable for independent commercialization in the United States.


Investor presentation

Click on Graphic Above to Download Presentation in PDF Format